Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer

BACKGROUND: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m(2)) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Lekha Madhavan, Kumar, R. Rejnish, Thomachan, Kainickal Cessal, Rafi, Malu, George, Preethi Sara, Krishna, K. M. Jagathnath, Ramadas, Kunnambath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
ORIGINAL ARTICLE: Head and Neck Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506812/
https://www.ncbi.nlm.nih.gov/pubmed/28702409
http://dx.doi.org/10.4103/2278-330X.208840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506812/
https://www.ncbi.nlm.nih.gov/pubmed/28702409
http://dx.doi.org/10.4103/2278-330X.208840

Ejemplares similares